Market Size of Leukapheresis Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 69.77 Billion |
Market Size (2029) | USD 98.55 Billion |
CAGR (2024 - 2029) | 7.15 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Leukapheresis Market Analysis
The Leukapheresis Market size is estimated at USD 69.77 billion in 2024, and is expected to reach USD 98.55 billion by 2029, growing at a CAGR of 7.15% during the forecast period (2024-2029).
- COVID-19 impacted the leukapheresis market due to disruption in non-essential procedures like leukapheresis, reduced availability of donors, and delayed clinical trials in order to increase focus on COVID-19-related research. For instance, as per an article published in January 2022 in BioMed Research Journal, blood donation dropped by 40% to 67% during the initial year of the pandemic in regions where travel restrictions were in place.
- Hence, owing to the factors mentioned above, COVID-19 had a significant impact on the studied market. However, the market is re-gaining its pre-pandemic nature regarding the demand for leukapheresis procedures, which in turn is expected to boost the utilization of leukapheresis devices. Furthermore, due to the increasing prevalence of leukemia and the growing demand for leukopaks in clinical research activities, the market is believed to witness significant growth over the forecast period.
- The rising incidence of leukemia disorders is expected to boost the demand by increasing the usage rates of leukapheresis machines and kits. For instance, according to the Leukemia Foundation 2022 update, an expected 19,403 Australians were diagnosed with a blood cancer such as leukemia, lymphoma, and myeloma in 2022. This was equivalent to 53 people per day or one person every 27 minutes. The same source stated that 135,000 people were living with blood cancer in Australia in 2022, and more than 275,000 Australians are expected to be living with blood cancer by 2035.
- Additionally, as per the report published by Blood Cancer UK in August 2022, blood cancer is the fifth most common cancer in the United Kingdom, with over 41,000 people being diagnosed with it every year. Hence, the rising burden of leukemia and blood cancer is creating the need for advanced therapeutics based on leukapheresis for treatment, which is expected to drive the market's growth over the forecast period.
- Furthermore, an article published in July 2021 in the International Journal of General Medicine stated that leukapheresis has emerged as one of the most essential adjuvant therapies to treat hyperleukocytosis, particularly in patients who were not unsuitable to cytoreduce with Ara-C or hydroxyurea. Leukapheresis is frequently used to treat a variety of illnesses. It is also employed for diagnostic purposes because it can boost the production of circulating tumor cells. The high number of research studies on leukapheresis is expected to propel the market growth during the forecast period.
- The rising company initiatives, such as product launches and technological advancements, are also contributing to growth in the leukapheresis market. For instance, in July 2021, Terumo Blood and Cell Technologies announced a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside. The company has expanded the functionality of Spectra Optia. The UVA PIT System ECP can now be performed using these devices as a functionally closed, online, multistep system with mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.
- Similarly, in June 2022, Terumo reported that the United States National Health Service (NHS) England acquired the Terumo's Spectra Optia Apheresis System to treat sickle cell disease. Such developments to increase the offerings of leukapheresis for healthcare professionals are expected to propel the market growth.
- Therefore, owing to the aforementioned factors, such as the high burden of blood cancer and rising strategic initiatives by market players for technological advancements and launches in leukapheresis, the studied market is anticipated to witness growth over the analysis period. However, the high cost of therapeutic leukapheresis and stringent regulatory issues for donor recruitment are expected to hinder the growth of the market during the forecast period.
Leukapheresis Industry Segmentation
Leukapheresis is used to collect blood stem cells or specific immune cells to be used as part of stem cell/bone marrow transplants in treating certain blood cancers.
The leukapheresis market is segmented by type (leukapheresis devices (apheresis devices, leukapheresis columns, cell separators, and leukoreduction filters) and leukapheresis disposables), application (therapeutic applications, research applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value in USD for the above segments.
By Type | |||||
| |||||
Leukapheresis Disposables |
By Application | |
Therapeutic Applications | |
Research Applications |
By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Leukapheresis Market Size Summary
The leukapheresis market is poised for significant growth over the forecast period, driven by the increasing prevalence of leukemia and the rising demand for leukopaks in clinical research. The market is recovering from the disruptions caused by the COVID-19 pandemic, which had led to a decrease in blood donations and delayed clinical trials. As the demand for leukapheresis procedures regains momentum, the utilization of leukapheresis devices is expected to rise. The market is further bolstered by advancements in therapeutic applications, such as the treatment of hyperleukocytosis and the production of circulating tumor cells, which underscore the importance of leukapheresis in both therapeutic and diagnostic settings. The introduction of innovative products and technological advancements by key players, such as Terumo Blood and Cell Technologies, is also contributing to market expansion.
The apheresis segment is anticipated to experience growth due to its increasing application in regenerative medicine and the extraction of platelet-rich plasma for therapeutic purposes. Strategic partnerships and expansions, such as those involving the National Health Service in England, are enhancing the market's reach and accessibility. North America is expected to hold a significant market share, driven by the high incidence of leukemia and lymphoma, alongside recent product launches aimed at supporting immunotherapy research. The market is characterized by a few major players who dominate through strategic alliances, acquisitions, and product innovations. Despite the high cost of therapeutic leukapheresis and regulatory challenges, the market is set to grow, supported by the rising burden of blood cancers and ongoing technological advancements.
Leukapheresis Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Leukemia
-
1.2.2 Growing Demand for Leukopaks in Clinical Research Activities
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Therapeutic Leukapheresis
-
1.3.2 Stringent Regulatory Issues for Donor Recruitment
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Type
-
2.1.1 Leukapheresis Devices
-
2.1.1.1 Apheresis Devices
-
2.1.1.2 Leukapheresis Columns and Cell Separators
-
2.1.1.3 Leukoreduction Filters
-
-
2.1.2 Leukapheresis Disposables
-
-
2.2 By Application
-
2.2.1 Therapeutic Applications
-
2.2.2 Research Applications
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Leukapheresis Market Size FAQs
How big is the Leukapheresis Market?
The Leukapheresis Market size is expected to reach USD 69.77 billion in 2024 and grow at a CAGR of 7.15% to reach USD 98.55 billion by 2029.
What is the current Leukapheresis Market size?
In 2024, the Leukapheresis Market size is expected to reach USD 69.77 billion.